Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

PHOREVER

financed

Closed

PHOtonic integrated OCT enhanced flow cytometry for canceR and cardiovascular di...

PHOtonic integrated OCT enhanced flow cytometry for canceR and cardiovascular diagnostics enabled by Extracellular VEsicles discRimination Imaging tools such as the Computed Tomography (CT) and the Magnetic Resonance Imaging (MRI) can offer diagnosis of the cancer and the cardiovascular disease (CVD), but not insight into the molecular mechanisms that promote their o... see more

30/06/2026

unknown leader

5M€

Project Budget: 5M€

Project leader unknown leader

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2022-11-17

HORIZON-CL4-2022-DIGITAL-EMERGING-01-35: Advanced characterisation methodolo... ExpectedOutcome:The development of reliable and practical tools to ensure the safe and sustainable u...

I+D

Cerrada

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 43 months Date Start: 2022-11-17
End date: 2026-06-30

Project leader unknown leader

Project Budget 5M€

participation deadline Sin fecha límite de participación.

Project description Imaging tools such as the Computed Tomography (CT) and the Magnetic Resonance Imaging (MRI) can offer diagnosis of the cancer and the cardiovascular disease (CVD), but not insight into the molecular mechanisms that promote their occurrence, progression and possible resistance to treatment. Information about these mechanisms is present however in the blood. Extracellular vesicles (EVs) are secreted into the blood, and can inform us about the state of their cells of origin, and by extension, about the presence and progression of diseases. Unfortunately, their detection is still imperfect due to the ultra-small size (50-200 nm) of most of them. PHOREVER will develop a disruptive multi-sensing platform that will enable for the first time the reliable detection of EVs with size down to 80 nm, the detection of EVs with specific biomarkers (proteins) on their surface, and the calculation of the corresponding EV concentrations in the blood. Its operation will be based on 3 sensing modalities: Flow-cytometry (FCM) with 4 wavelengths (405, 488, 633 and 785 nm) as the main modality for EV detection and size classification, dual-channel swept-source optical coherence tomography (SS-OCT) with 2.5 µm resolution for imaging of the sensing area and noise reduction of the FCM measurements, and fluorescence sensing at 488 nm for biomarker detection after staining. The key components will be the 2 photonic integrated circuits in TriPleX and the 3 microfluidic chips, which will be integrated as a compact point-of-care device. The medical impact can be ground-breaking. The first use case will be related to pancreatic cancer with focus on progression monitoring, metastasis risk assessment, and treatment efficacy evaluation. The second use case will be related to stroke with focus on its fast and precise diagnosis for time-to-treatment reduction. In either case, data analysis empowered by artificial intelligence will correlate the measurement data to disease specific medical information.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers